The earnings call reflects a positive outlook with significant advancements in product development, regulatory submissions, and strategic partnerships. Financial positioning is bolstered by recent fundraising and revenue from licensing agreements. However, increased R&D expenses and operating loss highlight ongoing financial challenges. Overall, the company's progress and potential overshadow the financial concerns.

Company Guidance

During the call, Scancell Holdings plc provided comprehensive guidance on its financial and operational progress for the fiscal year ended April 30, 2025. Key metrics highlighted include a reported revenue of GBP 4.7 million, largely attributed to their second commercial license agreement with Genmab, which included upfront payments totaling USD 6 million and potential further milestone payments up to $630 million. The company also successfully raised GBP 12.1 million in late 2024, strengthening its financial position with a cash reserve of GBP 16.9 million as of year-end. Research and development expenses were GBP 14.7 million, focusing on their SCOPE and MODIFY studies. The company anticipates a tax credit of approximately GBP 3 million, contributing to an operating loss of GBP 15 million. Scancell is optimistic about its cash runway extending into the second half of 2026, thanks to the recent financing and potential upside from future Genmab milestone payments. The company is poised for advanced regulatory discussions and aims to initiate randomized studies for iSCIB1+ in 2026, underlining a clear pathway toward commercialization and potential partnerships.

Partnership with Cancer Vaccine Launch Pad

Formed a major partnership with the cancer vaccine Launch Pad, highlighting strategic alliances.

iSCIB1+ Progression-Free Survival (PFS) Advantage

iSCIB1+ shows a PFS of 78% in advanced melanoma, compared to 46% for standard care.

Regulatory and Manufacturing Advancements

Documentation submitted to FDA and other regulators for iSCIB1+. Commercial-scale manufacturing process confirmed.

GlyMab Therapeutics Establishment

Established GlyMab Therapeutics, providing strategic optionality for antibody development.

Financial Position and Funding

Raised GBP 12.1 million in financing, ensuring a strong financial position moving forward.

Revenue from Genmab Licensing Agreement

Reported revenues of GBP 4.7 million from Genmab licensing, with potential for further milestone payments.

Modi-1 and GlyMab Assets Development

Progress in ModiFY study for Modi-1 in head and neck cancer, and GlyMab assets poised for further development.

Scancell Holdings (GB:SCLP) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:SCLP Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jan 29, 2026	2026 (Q2)	- / -	-0.014	―	―	―
Sep 11, 2025	2025 (Q4)	- / <0.01	-0.004	125.00% (<+0.01)	―	―
Jan 30, 2025	2025 (Q2)	- / -0.01	-0.003	-366.67% (-0.01)	―	―
Sep 24, 2024	2024 (Q4)	- / >-0.01	-0.011	63.64% (<+0.01)	―	―
Jan 30, 2024	2024 (Q2)	- / -	-0.004	―	―	―
Oct 31, 2023	2023 (Q4)	- / >-0.01	-0.004	25.00% (<+0.01)	―	―
Jan 25, 2023	2023 (Q2)	- / >-0.01	0.004	-200.00% (>-0.01)	―	―
Oct 28, 2022	2022 (Q4)	- / >-0.01	-0.016	62.50% (+0.01)	―	―
Jan 26, 2022	2022 (Q2)	- / <0.01	-0.007	157.14% (+0.01)	―	―
Oct 29, 2021	2021 (Q4)	- / -0.02	-0.006	-166.67% (-0.01)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:SCLP Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Sep 11, 2025	8.54p	8.90p	+4.22%
Jan 30, 2025	9.66p	10.00p	+3.52%
Sep 24, 2024	15.00p	14.00p	-6.67%
Jan 30, 2024	10.50p	11.30p	+7.62%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Scancell Holdings (GB:SCLP) report earnings?

Scancell Holdings (GB:SCLP) is schdueled to report earning on Jan 29, 2026, TBA (Confirmed).

What is Scancell Holdings (GB:SCLP) earnings time?

Scancell Holdings (GB:SCLP) earnings time is at Jan 29, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Scancell Holdings stock?

The P/E ratio of Scancell Holdings is N/A.

What is GB:SCLP EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing